Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform

Executive Summary

In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises

You may also be interested in...

Merck Names Ken Frazier President

The promotion moves Frazier one step closer to becoming CEO and Chairman when Dick Clark retires as expected next year.

Novo Nordisk's GLP-1 Victoza Off To A Good Start

New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.

With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate

Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts